Condition

Myelodysplastic Syndrome clinical trials and research

• 64Clinical trials
• 11NIH research projects
• 35Countries

Newest Myelodysplastic Syndrome clinical trials

All recruiting trials (64)

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• Nicotinamide Riboside and Pterostilbene in lower risk MDS and high-risk CCUS

  This phase 2 study tests whether nicotinamide riboside plus pterostilbene can help improve blood counts in adults with lower risk MDS or high-risk CCUS who are not transfusion-dependent.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT07579429

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Elritercept versus epoetin alfa for transfusion-dependent anemia in lower-risk MDS

  This study tests whether elritercept can reduce the need for red blood cell transfusions and improve fatigue compared with epoetin alfa in adults with very low-, low-, or intermediate-risk myelodysplastic syndromes who need regular transfusions.

  Recruiting at 103 sites Phase 3 Takeda · Gilbert, Arizona and 165 other locations · NCT07422480

• CD64 CAR T Therapy for Adults with Relapsed or Refractory AML

  This phase 1 study tests a patient’s own CD64-directed CAR T cells to see if they can be safely given and potentially help adults with relapsed or refractory AML.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT07347418

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Adding FHD-286 to low‑dose decitabine and venetoclax for adverse‑risk AML

  This trial tests whether adding FHD-286 to a low‑dose decitabine plus venetoclax regimen helps people with newly diagnosed adverse‑risk acute myeloid leukemia or AML that progressed after one prior therapy.

  Recruiting Phase 1 Montefiore Medical Center · The Bronx, New York · NCT07283094

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Induction and consolidation using fludarabine, cytarabine, idarubicin, and venetoclax for acute myeloid leukemia

  This trial tests whether adding venetoclax to induction and consolidation chemotherapy (fludarabine, cytarabine, and idarubicin) helps adults 18–65 with newly diagnosed acute myeloid leukemia or high-blast myelodysplastic syndrome achieve deeper remissions than standard cytarabine/daunorubicin therapy.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT07228273

• High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

  This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT07205523

• RPT1G for adults with relapsed or refractory acute myeloid leukemia and high-risk MDS

  This study will test whether the drug RPT1G is safe and find the best dose for adults whose AML or high-risk MDS has come back or not responded to treatment.

  Recruiting at 2 sites Phase 1 Remedy Plan, Inc. · New York, New York and 1 other locations · NCT07107126

• FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers

  This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07046078

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Adding emapalumab to standard post-transplant medicines to prevent graft‑versus‑host disease after reduced‑intensity donor stem cell transplant

  This trial will test whether adding emapalumab to post‑transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil can prevent graft‑versus‑host disease in adults with AML or MDS receiving a reduced‑intensity donor stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06996119

• Lower-dose ATG plus mini post‑transplant cyclophosphamide to prevent GVHD after haploidentical stem cell transplant

  This approach tries a lower dose of ATG combined with a short course of post‑transplant cyclophosphamide to prevent graft‑versus‑host disease in people aged 12–65 receiving a haploidentical stem cell transplant for acute leukemia or myelodysplastic syndrome.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT06984536

• Evaluating XS-04 for patients with relapsed or refractory blood cancers

  This study is testing a new tablet called XS-04 to see if it is safe and how well it works for people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 2 sites Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Beijing and 3 other locations · NCT06820268

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• HPV vaccination after allogeneic stem cell transplant

  This trial will test whether giving the 9‑valent HPV vaccine early or later after an allogeneic stem cell transplant produces a protective antibody response in adults up to age 45 who had a transplant.

  Recruiting at 3 sites Phase 2 Vastra Gotaland Region · Lund, Region Skåne and 4 other locations · NCT06793410

• Extracorporeal iron purification with MEX-CD1 for patients with MDS or myelofibrosis

  This study will try using an external blood-filter device (MEX-CD1) to remove excess iron in transfusion-dependent patients with myelodysplastic syndrome or myelofibrosis who cannot tolerate standard chelation.

  Recruiting at 2 sites Hospices Civils de Lyon · Oullins-Pierre-Bénite and 1 other locations · NCT06781099

• Exercise for patients with low-risk myeloid cancers

  This study is testing if a special exercise program can help people with low-risk myeloid cancers stay healthy and possibly prevent their condition from getting worse.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Denmark and 1 other locations · NCT06773871

• Preventing GVHD in children and young adults with blood cancers

  This study is testing a new treatment plan to see if it can help prevent graft-versus-host disease in children and young adults with blood cancers after they receive a transplant.

  Recruiting Phase 2/3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06756152

• Testing a new treatment for patients with specific myeloid cancers

  This study is testing a new treatment combining rezatapopt and azacitidine to see if it can help patients with specific myeloid cancers, like acute myeloid leukemia and myelodysplastic syndrome, feel better and live longer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Tampa, Florida and 1 other locations · NCT06616636

• Combining Enasidenib with Standard Treatment for Higher-Risk Myelodysplastic Syndrome

  This study is testing if adding a new drug called enasidenib to standard treatment can help people with higher-risk myelodysplastic syndrome and an IDH2 mutation achieve better remission rates.

  Recruiting at 147 sites Phase 2 National Cancer Institute (NCI) · Berkeley, California and 150 other locations · NCT06577441

• Using olutasidenib to prevent relapse in patients with IDH1 mutated blood cancers after transplant

  This study is testing if a new drug called olutasidenib can help prevent blood cancers from coming back in patients with a specific gene mutation after they have had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06543381

• Evaluating risks of myelodysplastic syndrome in patients receiving peptide radionuclide therapy

  This study is trying to find out if certain patients who receive a specific cancer treatment are at risk of developing blood disorders like myelodysplastic syndrome and leukemia, to make the treatment safer for everyone.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06510868

• Using tagraxofusp and azacitidine to prevent cancer recurrence after transplant in certain leukemia and syndrome patients

  This study is testing if a new combination of two drugs can help prevent cancer from coming back in people with certain types of leukemia and blood disorders after they have had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06498973

• Testing a new anti-cancer drug for patients with acute myeloid leukemia and myelodysplastic syndromes

  This study is testing a new anti-cancer drug called cirtuvivint, alone and with another drug, to see if it helps people with acute myeloid leukemia and myelodysplastic syndromes feel better and live longer.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · New Haven, Connecticut and 22 other locations · NCT06484062

• Restoring gut bacteria before stem cell transplant for blood cancer patients

  This study is testing if restoring gut bacteria with a special treatment before stem cell transplants can help blood cancer patients have better health and treatment outcomes.

  Recruiting at 6 sites Phase 2 Imperial College London · Birmingham, England and 7 other locations · NCT06355583

• Evaluating a new treatment for recurrent adult acute myeloid leukemia and myelodysplastic syndrome

  This study is testing a new combination treatment for adults with recurrent acute myeloid leukemia and myelodysplastic syndrome to see if it works better than current options.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06329999

• Using a new antibody treatment with chemotherapy and radiation for high-risk blood cancers before stem cell transplant

  This study is testing a new antibody treatment combined with chemotherapy and radiation to see if it can help people with high-risk blood cancers before they receive a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06287944

• Preventing Acute GVHD After Stem Cell Transplant

  This study is testing a new way to give a medication before and during stem cell transplants to see if it can help prevent a serious condition called acute GVHD in patients.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06265584

• Using ruxolitinib, tacrolimus, and methotrexate to prevent graft versus host disease in young patients after bone marrow transplant

  This study is testing if a combination of three medications can help prevent graft versus host disease in young patients after they receive a bone marrow transplant for certain types of leukemia or blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06128070

• Assessing the safety of luspatercept in Korean patients with myelodysplastic syndrome or beta thalassemia

  This study is testing how safe the drug luspatercept is for adult Korean patients with myelodysplastic syndrome or beta thalassemia while they are being treated.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06073860

• Curcumin for treating inflammation and symptoms in blood disorders

  This study is testing if a curcumin supplement can help reduce inflammation and improve symptoms in people with certain blood disorders.

  Recruiting at 2 sites Phase 2 University of Southern California · Los Angeles, California and 1 other locations · NCT06063486

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• At-home cancer treatment versus clinic-based treatment for advanced cancer patients

  This study tests whether giving cancer treatment at home is better for comfort and satisfaction compared to getting it at a clinic for people with advanced cancer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Jacksonville, Florida and 1 other locations · NCT05969860

• SP-420 to remove excess iron in adults with transfusion-dependent beta thalassemia or low‑risk MDS

  This will test whether SP-420 can clear excess liver iron in adults who receive regular transfusions for beta thalassemia or transfusion‑dependent low‑risk myelodysplastic syndrome.

  Recruiting Phase 2 Pharmacosmos A/S · Copenhagen · NCT05693909

• Screening to match myeloid cancer patients with treatment options

  This study is testing a new way to help people with acute myeloid leukemia or myelodysplastic syndrome find the right treatment options faster by checking their blood and bone marrow for specific markers.

  Recruiting at 345 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 359 other locations · NCT05564390

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Combination treatment for FLT3-mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of three drugs to see if it can help people with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome feel better and live longer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05010122

• Screening for pediatric leukemia in children with relapsed or difficult-to-treat cases

  This study is testing how to better screen children and young adults with tough cases of leukemia to see if they qualify for new treatment options.

  Recruiting at 174 sites Phase 1/2 PedAL BCU, LLC · Birmingham, Alabama and 183 other locations · NCT04726241

• Using venetoclax with busulfan to treat high-risk blood cancers

  This study is testing if combining venetoclax with busulfan, cladribine, and fludarabine can help people with high-risk blood cancers like acute myeloid leukemia and myelodysplastic syndrome do better after stem cell transplantation.

  Recruiting Phase 2/3 M.D. Anderson Cancer Center · Houston, Texas · NCT04708054

• Long-term study of blood diseases in patients in China

  This study is trying to gather detailed information from patients in China with blood diseases like leukemia and multiple myeloma to better understand how these conditions affect their lives and treatment options.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT04645199

• Combining CPX-351 and ivosidenib for treating IDH1 mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a combination of two treatments, CPX-351 and ivosidenib, to see if they can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome who have an IDH1 mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04493164

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Evaluating BTX-A51 for patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

  This study is testing a new drug called BTX-A51 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or high-risk myelodysplastic syndrome feel better and improve their treatment options.

  Recruiting at 3 sites Phase 1 Edgewood Oncology Inc. · Duarte, California and 2 other locations · NCT04243785

• Treatment of low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia with canakinumab

  This study is testing if a new medication called canakinumab can help people with low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia feel better and reduce their need for blood transfusions.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04239157

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Determining the best dose of CYAD-02 for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome

  This study is testing different doses of a new treatment called CYAD-02 to see which one works best for people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 4 sites Phase 1 Celyad Oncology SA · Jacksonville, Florida and 4 other locations · NCT04167696

• Strategies to reduce graft versus host disease in blood stem cell transplant patients with acute leukemia or MDS

  This study is testing two different treatment plans to see which one better helps prevent graft versus host disease in patients with acute leukemia or myelodysplastic syndrome after they receive a blood stem cell transplant.

  Recruiting at 3 sites Phase 2 Fred Hutchinson Cancer Center · Tampa, Florida and 2 other locations · NCT03970096

• Using enasidenib and azacitidine to treat patients with recurrent or refractory acute myeloid leukemia and IDH2 gene mutation

  This study is testing if a combination of two medications, enasidenib and azacitidine, can help people with recurrent or hard-to-treat acute myeloid leukemia that has an IDH2 gene mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03683433

• Using edetate calcium disodium or succimer to treat acute myeloid leukemia or myelodysplastic syndrome during chemotherapy

  This study is testing whether two drugs, edetate calcium disodium and succimer, can safely help people with acute myeloid leukemia or myelodysplastic syndrome feel better during chemotherapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03630991

• Combining Ivosidenib and Venetoclax with or without Azacitidine for treating IDH1 mutated blood cancers

  This study is testing a combination of two drugs, ivosidenib and venetoclax, with or without azacitidine, to see if it helps people with certain types of blood cancers that have an IDH1 mutation.

  Recruiting at 4 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 3 other locations · NCT03471260

• HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant

  This Phase 1 study will test whether giving specially engineered donor T cells called HA-1 TCR T cells is safe and what dose works for people whose acute leukemia came back or didn't respond after a donor stem cell transplant.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03326921

• Combining SL-401 with Azacitidine or Venetoclax for treating blood cancers

  This study is testing if combining a new treatment called SL-401 with existing drugs azacitidine or venetoclax can help people with certain blood cancers feel better and improve their outcomes.

  Recruiting at 3 sites Phase 1 Dana-Farber Cancer Institute · Duarte, California and 2 other locations · NCT03113643

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

• Personalized NK cell therapy after umbilical cord blood transplant for leukemia

  This study is testing if a special treatment using personalized immune cells from umbilical cord blood can help people with leukemia feel better after their transplant.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02727803

• Transplantation with modified stem cells and Zoledronate for pediatric cancers

  This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT02508038

• Combining cladribine, idarubicin, cytarabine, and venetoclax for treating certain blood cancers

  This study is testing a new combination of four medications to see if it helps people with certain types of blood cancers feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02115295

• Treating Aplastic Anemia and Myelodysplastic Syndrome with Combination Therapy

  This study is testing a combination of four treatments to see if it can help people with aplastic anemia or certain types of myelodysplastic syndrome improve their blood counts and overall health.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT01624805

• Monitoring minimal residual disease in patients with acute myeloid leukemia or myelodysplastic syndrome

  This study is trying to see if new tests can help find hidden cancer cells in patients with acute myeloid leukemia or myelodysplastic syndrome who seem to be in remission, to better understand their risk of relapse.

  Recruiting University of Rochester · Rochester, New York · NCT01311258

• Collection of tissue samples for cancer research

  This study is collecting tissue samples from adults and kids with cancer to help researchers learn more about the disease and improve treatments.

  Recruiting at 10 sites National Institutes of Health Clinical Center (CC) · Sacramento, California and 16 other locations · NCT00900198

NIH-funded research (11)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeting diverse stem cells in myelodysplastic syndrome to eradicate the disease

  Aimed at identifying weaknesses in the diverse stem cell populations of myelodysplastic syndrome so future treatments can wipe out the root cause of the disease.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11401024

• New treatment approach for myelodysplastic syndrome and acute myeloid leukemia

  This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.

  NIH research Avantgen, INC. · San Diego, United States · NIH-11189625

• Targeting metabolic weak spots in myelodysplastic syndrome stem cells

  The team is trying metabolism-based treatments to kill the stem cells that drive high-risk myelodysplastic syndrome (MDS).

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11188998

• Investigating the role of PI3 kinase in Myelodysplastic Syndrome

  This study is looking at how certain changes in genes might affect blood cell production in older adults with Myelodysplastic Syndrome (MDS), and it hopes to find new ways to help improve treatment for people with this condition.

  NIH research Albert Einstein College of Medicine · Bronx, United States · NIH-11112391

• Identifying harmful and harmless genetic variations in blood cancer predisposition genes

  This study is looking at how certain changes in a gene called DDX41 might affect the chances of developing blood disorders like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), so that doctors can provide better advice and support for patients at risk.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11090449

• Investigating CCRL2's role in myelodysplastic syndrome

  This study is looking at how a specific gene called CCRL2 affects the growth of harmful cells in myelodysplastic syndrome (MDS), especially in men, to find new ways to improve treatment for people with this blood disorder.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11076301

• Understanding how immune evasion occurs in high-risk myelodysplastic syndrome

  This study is looking at how a protein called VISTA helps high-risk myelodysplastic syndrome (HR-MDS) avoid being attacked by the immune system, with the goal of finding new ways to improve treatments for patients like you.

  NIH research Vanderbilt University · Nashville, UNITED STATES · NIH-11069224

• Targeting specific stem cells in myelodysplastic syndrome for better treatment outcomes

  This study is looking to find better ways to treat high-risk myelodysplastic syndrome (MDS) by understanding the different types of stem cells involved in the disease and testing a new combination of drugs to help improve patient outcomes.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10931676

• New treatment options for myelodysplastic syndrome and acute myeloid leukemia

  This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.

  NIH research Avantgen, INC. · San Diego, United States · NIH-10920336

• Understanding how U2AF1 mutations contribute to myelodysplastic syndrome

  This study is looking into how changes in the U2AF1 gene affect people with myelodysplastic syndrome (MDS), which could help us find better ways to diagnose and treat this blood disorder.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10873169

• Targeting CD117 with Astatine-211 to treat Acute Myeloid Leukemia and Myelodysplastic Syndrome

  This study is testing a new treatment that uses a special combination of antibodies and a radioactive substance to help patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by targeting cancer cells more directly while protecting healthy ones.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-10670383

Related topics

Quick answers

How many Myelodysplastic Syndrome clinical trials are recruiting right now?

64, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (50 trials), China (6 trials), Canada (4 trials), Puerto Rico (3 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 28, Phase 1: 20, Phase 1/2: 3, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →